Moscow Expands Covid-19 Vaccine Campaign as Drug Nears Approval
(Bloomberg) -- Some medical staff and city government workers in Moscow are being offered the opportunity to inoculate against the coronavirus as Russia is poised to register what it says is the world's first Covid-19 vaccine.
At least one hospital is preparing lists of employees who want to be vaccinated with the drug developed by Moscow's Gamaleya Institute, according to a doctor who received an invitation. A city government official said similar notices inviting volunteers for inoculation had been sent out to staff there.
An invitation seen by Bloomberg states that the vaccine is safe and has passed clinical trials. The Moscow City Government's press service declined to comment.
The Gamaleya vaccine developed with the Russian Direct Investment Fund is expected to get conditional registration this month, requiring trials on another 1,600 people, and production is likely to start in September, Deputy Prime Minister Tatyana Golikova told President Vladimir Putin at a July 29 meeting. Regulators plan to register the vaccine by Aug. 12, according to a person familiar with the process.
The developers are touting the vaccine as safe and effective amid a global race to develop protection against the deadly virus that's killed more than 700,000 worldwide and wreaked economic havoc as nations have locked down in response.
Still, the testing data hasn't been published and the speed with which Russia is moving to make the vaccine available has raised questions in other countries.
©2020 Bloomberg L.P.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.